Are we able to prevent the manifestation of diabetes type 2?;Můžeme zabránit manifestaci diabetu 2. typu?

Prakticky Lekar

Volumn 84, Issue 3, 2004, Pages 152-156

  Kvapil, Milan ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Diabetes mellitus type 2; Prevention; Risk factors

Indexed keywords

TETRAHYDROLIPSTATIN;

CLINICAL FEATURE; FAMILIAL DISEASE; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; REVIEW; RISK ASSESSMENT; WEIGHT REDUCTION;

EID: 1842526047     PISSN: 00326739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Chiasson, J. H., et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 359, 2002, s. 2072-2077.
2. Jensen, M. D.: Adipose tissue and fatty acid metabolism in humans. J. R. Soc. Med., 95, 2002, Suppl. 42, s. 3-7.
3. Hansson, L., et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular mortality and morbidity in hypertension: the Captopril Prevention Project (CAPP). Lancet, 353, 1999, s. 611-616.
4. Howlett, H. C. S., et al.: A risk -d benefit assessment of metformin in type 2 Diabetes Mellitus. Drug safety, 20, 1999, s. 489-503.
5. Lindholm, L. H., et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens., 20, 2002, s. 1879-1886.
6. Sjöström, L., et al.: XENDOS (Xenical in the prevention of Diabetes in Obese Subjects): a landmark study. Presentation in EADS 2002, Budapest.
7. Tuomilehto, J., et al.: Prevention of type e diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM, 344, 2001, s. 1343-1350.
8. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEJM, 342, 2000, s. 145-153.
9. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. NEJM, 346, 2002, s. 393-403.
10. The Antihypertensive and Lipid - Lovering treatment to prevent Heart Attack Trial (ALHAT). JAMA, 288, 2002, s. 1981-1997.
11. Charvát, J., et al.: Diabetes mellitus a kardiovaskulá rní komplikace. Praha: Triton, 2001, s. 204.